Search

How Can We Help You?

Video

Quick Info:

Find a Doctor Specialties (800) 213-3284

Go To Home PageBack

Solid Tumors

Select Clinical Trial

Protocol Number: NCI Protocol # 10323

Protocol Title: Cancer Moonshot Biobank Research Protocol

Eligibility: Men or women age 18 and older undergoing standard of care therapy for stage IV colorectal, stage III/IV lung, metastatic castration-resistant prostate, stage IV gastroesophageal, stage III/IV melanoma, or treatment refractory multiple myeloma cancers, and willing to provide longitudinal biospecimens.

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: BioAtla 3021-001

Protocol Title: A phase 1 or 2 dose escalation and dose expansion study of BA3021 alone and in combination with nivolumab in patients with advanced solid tumors.

Eligibility: Men and women age 18 and older with histologically or cytologically confirmed ROR2 positive locally advanced unresectable or metastatic NSCLC or melanoma after disease progression following PD-1/L-1, EGFR inhibitor, or ALK inhibitor therapy.

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: Chair Exercise

Protocol Title: A randomized pragmatic chair-based home exercise intervention for mitigating cancer-related fatigue in older adults undergoing chemotherapy for advanced disease

Eligibility: Men and women aged 70 and older with advanced cancer, reporting moderate to severe fatigue, and less than 60 minutes of physical activity per week.

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: S2013

Protocol Title: Immune Checkpoint Inhibitor Toxicity (I-CHECKIT): A Prospective Observational Study

Eligibility: Men or women age 18 and older, planning to receive immunotherapy only for a solid tumor malignancy.

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: Mirati Krystal MRTX849

Protocol Title: A Phase 1/2 Multiple Expansion Cohort Trial of MRTX849 in Patients with Advanced Solid Tumors with KRAS G12C Mutation

Eligibility: Men or women, ages 18 and older, diagnosed with advanced cancer, which has a KRAS G12C mutation. 

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: EAY131/MATCH

Protocol Title: Molecular Analysis for Therapy Choice (MATCH)

Eligibility: Men or women, ages 18 and older whose cancer has not responded to conventional treatment or whose cancer does not have a known effective treatment. Patients/treating physician must have received notification of actionable mutation of interest(aMOI) following genetic testing of tumor at an accepted outside laboratory such as Foundation One, Caris, etc.

Contact Information: (910) 715-2200

____________________________________________________________________________________________

Protocol Number: Seattle Genetics SGNLVA-005; NCT04032704

Protocol Title: Open-Label Phase 2 Study of Ladiratuzumab Vedotin (LV) for Unresectable Locally Advanced or Metastatic Solid Tumors

Eligibility: Men and women age 18 and older diagnosed with Castrate Resistant Prostate cancer or Melanoma who have progressed following their first line of therapy.

Contact Information: (910) 715-2200

__________________________________________________________________________________________

Protocol Number: S2012

Protocol Title: Addition of Atezolizumab (Immunotherapy) to Standard Chemotherapy   

Eligibility: Men and Women, 18 years or older with Non-lung, metastatic Small Cell Neuroendocrine Cancer

Contact Information: (910) 715-2200

__________________________________________________________________________________________

Protocol Number: Neuwave Flex MC Neu_2020_03

Protocol Title:  A Prospective Multicenter Study of Transbronchial Microwave Ablation Using Robotic-Assisted Bronchoscopy in Subjects with Oligometastatic Tumors in the Lung

Eligibility: Men or women, ages 22 and older, with colorectal, renal or sarcoma tumors in the lung

Contact Information: (910) 715-2200

__________________________________________________________________________________________

Protocol Number: URCC- 21038 Direct

Protocol Title:  Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT):  A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

Eligibility: Black or white, men or women, ages 18 and older, scheduled to receive cancer treatment with Immunotherapy

Contact Information: (910) 715-2200

Contact Information: (910) 715-2200

Specialties
Clara McLean House
Make a Donation
News & Events